Cargando…

Comparison of treatment plans for hypofractionated high‐dose prostate cancer radiotherapy using the Varian Halcyon and the Elekta Synergy platforms

PURPOSE: To compare radiotherapy plans between an O‐ring and a conventional C‐arm linac for hypofractionated high‐dose prostate radiotherapy in terms of plan quality, dose distribution, and quality assurance in a multi‐vendor environment. METHODS: Twenty prostate cancer treatment plans were irradiat...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamihardja, Jörg, Razinskas, Gary, Exner, Florian, Richter, Anne, Kessler, Patrick, Weick, Stefan, Kraft, Johannes, Mantel, Frederick, Flentje, Michael, Polat, Bülent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425948/
https://www.ncbi.nlm.nih.gov/pubmed/34351055
http://dx.doi.org/10.1002/acm2.13380
_version_ 1783749946384580608
author Tamihardja, Jörg
Razinskas, Gary
Exner, Florian
Richter, Anne
Kessler, Patrick
Weick, Stefan
Kraft, Johannes
Mantel, Frederick
Flentje, Michael
Polat, Bülent
author_facet Tamihardja, Jörg
Razinskas, Gary
Exner, Florian
Richter, Anne
Kessler, Patrick
Weick, Stefan
Kraft, Johannes
Mantel, Frederick
Flentje, Michael
Polat, Bülent
author_sort Tamihardja, Jörg
collection PubMed
description PURPOSE: To compare radiotherapy plans between an O‐ring and a conventional C‐arm linac for hypofractionated high‐dose prostate radiotherapy in terms of plan quality, dose distribution, and quality assurance in a multi‐vendor environment. METHODS: Twenty prostate cancer treatment plans were irradiated on the O‐ring Varian Halcyon linac and were re‐optimized for the C‐arm Elekta Synergy Agility linac. Dose‐volume histogram metrics for target coverage and organ at risk dose, quality assurance, and monitor units were retrospectively compared. Patient‐specific quality assurance with ion chamber measurements, gamma index analysis, and portal dosimetry was performed using the Varian Portal Dosimetry system and the ArcCHECK(®) phantom (Sun Nuclear Corporation). Prostate‐only radiotherapy was delivered with simultaneous integrated boost (SIB) volumetric modulated arc therapy (VMAT) in 20 fractions of 2.5/3.0 Gy each. RESULTS: For both linacs, target coverage was excellent and plan quality comparable. Homogeneity in PTV(Boost) was high for Synergy as well as Halcyon with a mean homogeneity index of 0.07 ± 0.01 and 0.05 ± 0.01, respectively. Mean dose for the organs at risk rectum and bladder differed not significantly between the linacs but were higher for the femoral heads and penile bulb for Halcyon. Quality assurance showed no significant differences in terms of ArcCHECK gamma pass rates. Median pass rate for 3%/2 mm was 99.3% (96.7 to 99.8%) for Synergy and 99.8% (95.6 to 100%) for Halcyon. Agreement between calculated and measured dose was high with a median deviation of −0.6% (−1.7 to 0.8%) for Synergy and 0.2% (−0.6 to 2.3%) for Halcyon. Monitor units were higher for the Halcyon by approximately 20% (p < 0.001). CONCLUSION: Hypofractionated high‐dose prostate cancer SIB VMAT on the Halcyon system is feasible with comparable plan quality in reference to a standard C‐arm Elekta Synergy linac.
format Online
Article
Text
id pubmed-8425948
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-84259482021-09-13 Comparison of treatment plans for hypofractionated high‐dose prostate cancer radiotherapy using the Varian Halcyon and the Elekta Synergy platforms Tamihardja, Jörg Razinskas, Gary Exner, Florian Richter, Anne Kessler, Patrick Weick, Stefan Kraft, Johannes Mantel, Frederick Flentje, Michael Polat, Bülent J Appl Clin Med Phys Radiation Oncology Physics PURPOSE: To compare radiotherapy plans between an O‐ring and a conventional C‐arm linac for hypofractionated high‐dose prostate radiotherapy in terms of plan quality, dose distribution, and quality assurance in a multi‐vendor environment. METHODS: Twenty prostate cancer treatment plans were irradiated on the O‐ring Varian Halcyon linac and were re‐optimized for the C‐arm Elekta Synergy Agility linac. Dose‐volume histogram metrics for target coverage and organ at risk dose, quality assurance, and monitor units were retrospectively compared. Patient‐specific quality assurance with ion chamber measurements, gamma index analysis, and portal dosimetry was performed using the Varian Portal Dosimetry system and the ArcCHECK(®) phantom (Sun Nuclear Corporation). Prostate‐only radiotherapy was delivered with simultaneous integrated boost (SIB) volumetric modulated arc therapy (VMAT) in 20 fractions of 2.5/3.0 Gy each. RESULTS: For both linacs, target coverage was excellent and plan quality comparable. Homogeneity in PTV(Boost) was high for Synergy as well as Halcyon with a mean homogeneity index of 0.07 ± 0.01 and 0.05 ± 0.01, respectively. Mean dose for the organs at risk rectum and bladder differed not significantly between the linacs but were higher for the femoral heads and penile bulb for Halcyon. Quality assurance showed no significant differences in terms of ArcCHECK gamma pass rates. Median pass rate for 3%/2 mm was 99.3% (96.7 to 99.8%) for Synergy and 99.8% (95.6 to 100%) for Halcyon. Agreement between calculated and measured dose was high with a median deviation of −0.6% (−1.7 to 0.8%) for Synergy and 0.2% (−0.6 to 2.3%) for Halcyon. Monitor units were higher for the Halcyon by approximately 20% (p < 0.001). CONCLUSION: Hypofractionated high‐dose prostate cancer SIB VMAT on the Halcyon system is feasible with comparable plan quality in reference to a standard C‐arm Elekta Synergy linac. John Wiley and Sons Inc. 2021-08-05 /pmc/articles/PMC8425948/ /pubmed/34351055 http://dx.doi.org/10.1002/acm2.13380 Text en © 2021 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals LLC on behalf of American Association of Physicists in Medicine https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Radiation Oncology Physics
Tamihardja, Jörg
Razinskas, Gary
Exner, Florian
Richter, Anne
Kessler, Patrick
Weick, Stefan
Kraft, Johannes
Mantel, Frederick
Flentje, Michael
Polat, Bülent
Comparison of treatment plans for hypofractionated high‐dose prostate cancer radiotherapy using the Varian Halcyon and the Elekta Synergy platforms
title Comparison of treatment plans for hypofractionated high‐dose prostate cancer radiotherapy using the Varian Halcyon and the Elekta Synergy platforms
title_full Comparison of treatment plans for hypofractionated high‐dose prostate cancer radiotherapy using the Varian Halcyon and the Elekta Synergy platforms
title_fullStr Comparison of treatment plans for hypofractionated high‐dose prostate cancer radiotherapy using the Varian Halcyon and the Elekta Synergy platforms
title_full_unstemmed Comparison of treatment plans for hypofractionated high‐dose prostate cancer radiotherapy using the Varian Halcyon and the Elekta Synergy platforms
title_short Comparison of treatment plans for hypofractionated high‐dose prostate cancer radiotherapy using the Varian Halcyon and the Elekta Synergy platforms
title_sort comparison of treatment plans for hypofractionated high‐dose prostate cancer radiotherapy using the varian halcyon and the elekta synergy platforms
topic Radiation Oncology Physics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425948/
https://www.ncbi.nlm.nih.gov/pubmed/34351055
http://dx.doi.org/10.1002/acm2.13380
work_keys_str_mv AT tamihardjajorg comparisonoftreatmentplansforhypofractionatedhighdoseprostatecancerradiotherapyusingthevarianhalcyonandtheelektasynergyplatforms
AT razinskasgary comparisonoftreatmentplansforhypofractionatedhighdoseprostatecancerradiotherapyusingthevarianhalcyonandtheelektasynergyplatforms
AT exnerflorian comparisonoftreatmentplansforhypofractionatedhighdoseprostatecancerradiotherapyusingthevarianhalcyonandtheelektasynergyplatforms
AT richteranne comparisonoftreatmentplansforhypofractionatedhighdoseprostatecancerradiotherapyusingthevarianhalcyonandtheelektasynergyplatforms
AT kesslerpatrick comparisonoftreatmentplansforhypofractionatedhighdoseprostatecancerradiotherapyusingthevarianhalcyonandtheelektasynergyplatforms
AT weickstefan comparisonoftreatmentplansforhypofractionatedhighdoseprostatecancerradiotherapyusingthevarianhalcyonandtheelektasynergyplatforms
AT kraftjohannes comparisonoftreatmentplansforhypofractionatedhighdoseprostatecancerradiotherapyusingthevarianhalcyonandtheelektasynergyplatforms
AT mantelfrederick comparisonoftreatmentplansforhypofractionatedhighdoseprostatecancerradiotherapyusingthevarianhalcyonandtheelektasynergyplatforms
AT flentjemichael comparisonoftreatmentplansforhypofractionatedhighdoseprostatecancerradiotherapyusingthevarianhalcyonandtheelektasynergyplatforms
AT polatbulent comparisonoftreatmentplansforhypofractionatedhighdoseprostatecancerradiotherapyusingthevarianhalcyonandtheelektasynergyplatforms